By Josh Beckerman
Shares of Madrigal Pharmaceuticals were down 2%, to $302.88, after the biopharmaceutical company increased the size of a stock-sale agreement and reported first-quarter results.
The company said an amendment to a 2021 sales agreement increased by $200 million the amount of stock it may sell from time to time.
For…
Read the full article here